Skip to Content

Nykode Therapeutics AS Ordinary Shares NYKD

Morningstar Rating
NOK 13.41 +0.25 (1.90%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NYKD is trading within a range we consider fairly valued.
Price
NOK 13.15
Fair Value
NOK 76.55
Uncertainty
Extreme
1-Star Price
NOK 853.15
5-Star Price
NOK 5.34
Economic Moat
Dwlpp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NYKD is a good fit for your portfolio.

News

Trading Information

Previous Close Price
NOK 13.16
Day Range
NOK 13.0613.47
52-Week Range
NOK 12.3830.86
Bid/Ask
NOK 12.50 / NOK 13.75
Market Cap
NOK 4.38 Bil
Volume/Avg
425,178 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
28.50
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
168

Comparables

Valuation

Metric
NYKD
CGEM
PTGX
Price/Earnings (Normalized)
Price/Book Value
2.431.484.39
Price/Sales
28.5024.24
Price/Cash Flow
Price/Earnings
NYKD
CGEM
PTGX

Financial Strength

Metric
NYKD
CGEM
PTGX
Quick Ratio
7.9116.6016.54
Current Ratio
8.0417.0716.71
Interest Coverage
−235.75
Quick Ratio
NYKD
CGEM
PTGX

Profitability

Metric
NYKD
CGEM
PTGX
Return on Assets (Normalized)
−19.18%−24.60%−16.60%
Return on Equity (Normalized)
−26.31%−25.95%−18.20%
Return on Invested Capital (Normalized)
−30.96%−29.67%−23.45%
Return on Assets
NYKD
CGEM
PTGX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSsmfvxqnjZjp$557.8 Bil
VRTX
Vertex Pharmaceuticals IncVrdjrprmDxrzwsx$103.3 Bil
REGN
Regeneron Pharmaceuticals IncKgngbtdHlwfnd$98.8 Bil
MRNA
Moderna IncGmzhplcsPpkql$38.8 Bil
ARGX
argenx SE ADRLdtlsfzxWkgj$21.3 Bil
BNTX
BioNTech SE ADRXzgnhylxXsww$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncNmfppwcScwgsq$18.4 Bil
BMRN
Biomarin Pharmaceutical IncNjxblzwrcCbwfqc$17.0 Bil
RPRX
Royalty Pharma PLC Class ALlcfwntbZprbgv$12.4 Bil
INCY
Incyte CorpDlsvmngqnTdwcfp$11.9 Bil

Sponsor Center